Octapharma

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Octapharma sits in the top decile of US sponsors by registered trial count (#415 of 15,742 sponsors by registered trial count).

43 total trials 9 currently recruiting 29 completed later-stage tilt top decile by trial count

Octapharma: 43 sponsored US clinical trials, 9 recruiting.

Octapharma sponsors 43 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 29 completed. 32 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Severe Hemophilia A, with 2 trials.

Top-decile sponsor footprint

Octapharma ranks in the top decile of sponsors by registered trial count (#415 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 59/100

29 of 33 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

43 total, page 1 of 1

RECRUITING Phase 4

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580
RECRUITING

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

NCT06429787
RECRUITING Phase 3

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116
RECRUITING Phase 3

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
RECRUITING Phase 4

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT05935358
RECRUITING Phase 3

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

NCT04929236
RECRUITING Phase 3

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173
RECRUITING Phase 3

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

NCT04867837
RECRUITING

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

NCT03695978
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

NCT04640142
COMPLETED Phase 3

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

NCT05523297
COMPLETED Phase 3

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

NCT04953884
COMPLETED Phase 3

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

NCT04508530
COMPLETED Phase 3

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030
COMPLETED Phase 3

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

NCT04052698
COMPLETED Phase 3

Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

NCT04400058
TERMINATED Phase 4

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

NCT03866798
COMPLETED Phase 3

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533
COMPLETED

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

NCT04053699
COMPLETED Phase 3

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335
TERMINATED

Octaplas Adult TTP Trial

NCT01938404
COMPLETED Phase 3

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

NCT02728752
COMPLETED Phase 3

Clinical Phase III Study TO Monitor THE Safety, Tolerability AND Efficacy OF Subcutaneous Human Immunoglobulin (octanorm) IN Patients With Primary Immunodeficiency Diseases, Including (BUT NOT Limited TO) Those WHO Have Completed THE Scgam-01 Trial

NCT03907241
TERMINATED

Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

NCT02037373
COMPLETED Phase 3

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

NCT02256917
COMPLETED Phase 4

Octaplas Pediatric Plasma Exchange Trial

NCT01938378
COMPLETED

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

NCT02962765
COMPLETED Phase 4

Octaplas Pediatric Plasma Replacement Trial

NCT02050841
COMPLETED Phase 3

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

NCT02267226
COMPLETED Phase 3

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

NCT01992549
COMPLETED Phase 3

Study of Octanorm Subcutaneous IG in Patients With PID

NCT01888484
COMPLETED Phase 2

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

NCT01575756
COMPLETED

Octagam 5% Versus Comparator Post Marketing Trial

NCT01859754
COMPLETED Phase 3

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

NCT01712438
COMPLETED

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

NCT01602419
COMPLETED Phase 3

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

NCT01365546
COMPLETED Phase 3

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

NCT01341912
COMPLETED Phase 3

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

NCT01313507
COMPLETED Phase 2

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

NCT00989196
COMPLETED Phase 3

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

NCT01012323
COMPLETED Phase 2

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

NCT00812565
COMPLETED Phase 3

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

NCT00618098
TERMINATED Phase 3

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00411801

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 27
Phase 4 5

Therapeutic Areas

Severe Hemophilia A 2
Prevent Bleeding in Major Surgery 1
Reversal of Anticoagulant Treatment 1
Adverse Effects in the Therapeutic Use of Plasma Substitutes 1
Primary Immunodeficiency Diseases 1
Acquired Antithrombin Deficiency 1
Acute Major Bleeding 1
Haemophilia A 1
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy 1
Acute Hereditary Angio Edema 1

Where Octapharma enrollment is open (later-stage tilt)

9 recruiting of 43 indexed (21% open); 29 completed (67%).

Phase mix: 32 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Severe Hemophilia A (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Octapharma: open-pipeline peers nationwide

Peers matched on 43 registered trials and 21% open enrollment, not the therapeutic-area sidebar.

Octapharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 20406080 0%5%10%15%20%25% Total trials Recruiting share OctapharmaAtlantic Health SystemCumberland PharmaceuticalsLahey ClinicSeattle Institute for Biomedical and Clinical ResearchGeorgia Institute of TechnologyInSightecW.L.Gore & AssociatesNova Southeastern University
Octapharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Octapharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 43 trials (± recruiting share)

Sponsors near 21% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Octapharma page

43 registered trials is a research-attention snapshot, not an endorsement of Octapharma or any single study.

  • 9 of Octapharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Severe Hemophilia A is the condition Octapharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Severe Hemophilia A trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Octapharma pipeline card: 43 registered trials from official public datasets.Report a data error.